drugset / Trial / NCT06254742
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
RandomizedCrossoverOpen-labelPrevention
Summary
The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.
Timeline
- Start
- 2024-02
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
Outcome
Outcome not reported
Stopped (Business): “The sponsor's R\&D strategy is adjusted.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Auto-HHPG-19K | Unknown | — | — |
| Subject | Mecapegfilgrastim | Protein / enzyme biologic | — | — |